Form 4 for EW Edwards Lifesciences
Accepted 2023-05-11 00:00:00 ET · period of report 2023-05-07 · accession 0001225208-23-005754 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-05-11 | 2023-05-10 | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | G - Gift | $0.00 | -9,500 | 95.6K | -9% | $0 |
| DI | 2023-05-11 | 2023-05-10 | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | G - Gift | $0.00 | +9,500 | 3.62M | +0.3% | $0 |
| DM | 2023-05-11 | 2023-05-10 | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | S - Sale+OE | $88.49 | -19.9K | 81.7K | -20% | -$1.76M |
| DM | 2023-05-11 | 2023-05-07+ | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | M - OptEx | $20.62 | +50.2K | 81.7K | +159% | +$1.03M |
| DM | 2023-05-11 | 2023-05-07+ | EW | MUSSALLEM MICHAEL A | COB, CEO, Dir | M - OptEx | $0.00 | -50.2K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-10 | G | D | 9,500 | $0.00 | 95,615.82 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-10 | G | A | 9,500 | $0.00 | 3,616,922 | I | — | — | |
| 3 | Common | Common Stock | 2023-05-10 | S | D | 5,984 | $88.94 | 105,115.82 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $88.84 to $89.25 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Common | Common Stock | 2023-05-10 | M | A | 29,375 | $35.20 | 111,099.82 | D | — | — | |
| 5 | Common | Common Stock | 2023-05-07 | M | A | 20,777 | $0.00 | 81,724.82 | D By Living Trust | — | — | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 6 | Common | Common Stock | 2023-05-10 | S | D | 13,891 | $88.29 | 81,724.82 | D | — | — | (F4) This transaction was executed in multiple trades at prices ranging from $87.83 to $88.83 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 7 | Derivative | Performance Rights | 2023-05-07 | M | D | 20,777 | $0.00 | 5,698 | D | — · 2023-05-07 to 2027-05-06 | 20,777 Common Stock | (F1) On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4. |
| 8 | Derivative | Employee Stock Option (Right to Acquire) | 2023-05-10 | M | D | 29,375 | $0.00 | 0 | D | $35.20 · 2016-06-12 to 2023-05-11 | 29,375 Common Stock |